JP2017500017A - 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 - Google Patents

生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Download PDF

Info

Publication number
JP2017500017A
JP2017500017A JP2016532136A JP2016532136A JP2017500017A JP 2017500017 A JP2017500017 A JP 2017500017A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A JP2017500017 A JP 2017500017A
Authority
JP
Japan
Prior art keywords
culture
cells
cell
liters
cumulative amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500017A5 (enExample
Inventor
ウィリアム シー． ヤン，
ウィリアム シー． ヤン，
ジウイー ル，
ジウイー ル，
ヤオ−ミン フアン，
ヤオ−ミン フアン，
ハン ユアン，
ハン ユアン，
ラシュミ クシルサガル，
ラシュミ クシルサガル，
トーマス リル，
トーマス リル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2017500017A publication Critical patent/JP2017500017A/ja
Publication of JP2017500017A5 publication Critical patent/JP2017500017A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016532136A 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Withdrawn JP2017500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919629P 2013-12-20 2013-12-20
US61/919,629 2013-12-20
PCT/US2014/071701 WO2015095809A1 (en) 2013-12-20 2014-12-19 Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000268A Division JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Publications (2)

Publication Number Publication Date
JP2017500017A true JP2017500017A (ja) 2017-01-05
JP2017500017A5 JP2017500017A5 (enExample) 2018-02-08

Family

ID=52347449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016532136A Withdrawn JP2017500017A (ja) 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Country Status (4)

Country Link
US (2) US20160289633A1 (enExample)
EP (1) EP3083933B1 (enExample)
JP (3) JP2017500017A (enExample)
WO (1) WO2015095809A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083933B1 (en) 2013-12-20 2026-01-21 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
US20180312802A1 (en) * 2015-11-02 2018-11-01 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins in perfusion mode
CN116083345A (zh) 2016-01-26 2023-05-09 勃林格殷格翰国际公司 对连续流动搅拌釜反应器细胞培养系统的连接灌注
EP3504315A4 (en) 2016-08-27 2020-04-15 3D Biotek, LLC BIOREACTOR
KR20250151558A (ko) 2017-10-06 2025-10-21 론자 리미티드 라만 분광법을 사용하는 세포 배양의 자동 제어
CN118580928A (zh) 2017-10-16 2024-09-03 里珍纳龙药品有限公司 灌注生物反应器及相关使用方法
WO2019094333A1 (en) * 2017-11-13 2019-05-16 Amgen Inc. Methods for producing protein products
TWI827570B (zh) * 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
US12365865B2 (en) * 2018-04-29 2025-07-22 Regenxbio Inc. Scalable clarification process for recombinant AAV production
US12071607B2 (en) * 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
JP7453151B2 (ja) * 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
CA3127629A1 (en) * 2019-01-25 2020-07-30 Biogen Ma Inc. Seed culture process for aav production
KR20220039777A (ko) * 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
EP4058547A1 (en) 2019-11-15 2022-09-21 Lonza Ltd. Process and system for producing an inoculum
JP7791210B2 (ja) 2021-05-03 2025-12-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スペソリマブを産生するための方法
WO2023114897A2 (en) 2021-12-15 2023-06-22 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
JP2025509328A (ja) * 2022-03-07 2025-04-11 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 改良されたバッチａａｖ産生システムおよび方法
IL319171A (en) * 2022-09-06 2025-04-01 Amgen Inc Lean cell culture perfusion methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
JP4176472B2 (ja) 2000-12-20 2008-11-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン 哺乳動物細胞の種連続増殖（ｓｅｅｄ−ｔｒａｉｎｅｘｐａｎｓｉｏｎ）のための装置及び方法
CA2457429A1 (en) 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
PT1486785E (pt) 2002-02-21 2011-05-12 Tokyo Gas Co Ltd Agentes de teste para avalia??o de efeito farmacol?gico de f?rmaco, e m?todo e reagentes para rastreio de f?rmaco que tem excelente efeito de administra??o e/ou pequeno efeito secund?rio de entre f?rmacos compreendendo enzimas, inibidores enzim?ticos
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2456015T3 (es) * 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
EP2527425A1 (en) * 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
CA2702363A1 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
RU2010146387A (ru) 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
EP2282767A4 (en) 2008-04-16 2012-07-11 Bayer Healthcare Llc MODIFICATION OF FACTOR IX ORIENTED SITE
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
AU2009240386A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
CA2727006A1 (en) * 2008-06-13 2009-12-17 Centocor Ortho Biotech Inc. Methods for obtaining high viable cell density in mammalian cell culture
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011207425A1 (en) * 2010-01-25 2012-08-16 Ventria Bioscience Methods and compositions for improving protein production
CA2804280A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
MY166954A (en) 2010-07-09 2018-07-25 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP2686415B1 (en) 2011-03-18 2017-11-15 GE Healthcare Bio-Sciences AB Flexible bag for cultivation of cells
KR20230114317A (ko) * 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
EP3083933B1 (en) 2013-12-20 2026-01-21 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PADAWER ISHAI ET AL.: "Case Study: An accelerated 8-day monoclonal antibody production process based on high seeding densit", BIOTECHNOLOGY PROGRESS, vol. 29, no. 3, JPN6018041861, 18 April 2013 (2013-04-18), pages 829 - 832, ISSN: 0004230568 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP7684224B2 (ja) 2019-04-11 2025-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP7680418B2 (ja) 2019-07-16 2025-05-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造

Also Published As

Publication number Publication date
JP2023022317A (ja) 2023-02-14
EP3083933A1 (en) 2016-10-26
JP2020054388A (ja) 2020-04-09
WO2015095809A1 (en) 2015-06-25
US20250382568A1 (en) 2025-12-18
EP3083933B1 (en) 2026-01-21
US20160289633A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
US20250382568A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fedbatch production capacity and product quality
KR101540124B1 (ko) 항노화 화합물을 사용하는 단백질의 생산 방법
KR102604988B1 (ko) 관류 배지
KR102604992B1 (ko) 관류 배지
US10676772B2 (en) Control of protein glycosylation by culture medium supplementation and cell culture process parameters
JP2024050574A (ja) 哺乳動物細胞培養物によって生産されるニューブラスチン抗体
US20150353883A1 (en) Medium Supplements for Improved Process Performance
JP7495483B2 (ja) 濃縮灌流培地
US12441980B2 (en) Methods for overcoming glutamine deprivation during mammalian cell culture
US10717965B2 (en) Mammalian cell culture-produced neublastin antibodies
JP2021503916A (ja) 哺乳動物細胞の培養方法
US20170029859A1 (en) Medium supplements for improved process performance
US20170327786A1 (en) Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
HK1142095B (en) Methods of protein production using anti-senescence compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200319